Oncolytic Virus Market Set to Advance Cancer Immunotherapy Frontier Through 2034 | Says DelveInsight

The Oncolytic Virus (OV) therapy landscape is evolving rapidly as this novel immuno-oncology strategy gains traction for its ability to selectively infect, replicate within, and destroy cancer cells, while simultaneously stimulating a potent anti-tumor immune response. Unlike traditional cancer treatments, oncolytic viruses offer dual mechanisms of action: direct tumor lysis and immune activation, making them promising candidates for combination regimens in hard-to-treat and resistant tumors.
DelveInsight's "Oncolytic Virus Market Report [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]" provides a comprehensive analysis of the current and forecasted market landscape across key geographies, including the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. The report covers insights into historical and projected epidemiology, disease burden, addressable patient pool, and treatment trends for malignancies where OV therapies are gaining clinical ground, such as melanoma, glioblastoma, hepatocellular carcinoma, and pancreatic cancer.

The oncolytic virus market is poised for growth driven by increased clinical trial activity, rising investment in cancer immunotherapy, and favorable regulatory pathways. The success of FDA-approved T-VEC (talimogene laherparepvec) in melanoma has paved the way for a growing pipeline of genetically engineered viruses, including HSV-based, adenovirus-based, and reovirus-based platforms. Companies like Replimune, Oncolys BioPharma, Sorrento Therapeutics, and Lokon Pharma are actively developing next-generation OV agents that promise greater efficacy and broader tumor targeting.

Despite regulatory and manufacturing complexities, the increasing integration of OV therapies with immune checkpoint inhibitors and CAR-T therapies is expected to unlock new therapeutic synergies and expand treatment opportunities across solid and hematologic malignancies.

This report provides an in-depth assessment of the oncolytic virus market size, key competitors, late-stage assets, ongoing clinical studies, and upcoming commercial opportunities. It is a valuable resource for pharma companies, investors, and researchers aiming to explore the future of viral immunotherapy in oncology.

Some of the Key Facts of the Oncolytic Virus Market Report:

- According to DelveInsight, the Oncolytic Virus market is expected to grow significantly by 2034.

- Breast cancer cases in the U.S. are projected to grow from 274,375 (2022) to 321,295 by 2035 (GLOBOCAN).

- Prostate cancer made up about 20% of the target population for oncolytic virus therapies in the 7MM in 2023 (DelveInsight).

- Melanoma is currently the main focus of oncolytic virus therapies, but Non-Melanoma Skin Cancer is expected to take the lead in the future.

- In 2023, melanoma represented around 10% of selected cancer incidences in the 7MM.

- In January 2025, the FDA granted orphan drug designation to ELC-100 (AdVince), an investigational oncolytic virus, for the treatment of pancreatic neuroendocrine tumors (NETs), according to Elicera Therapeutics, AB.

- In November 2024, Mustang Bio announced that the FDA granted orphan drug designation to MB-108, a herpes simplex virus type 1 oncolytic virus and a component of MB-109, for the treatment of malignant glioma. MB-109 combines MB-101, a CAR-T cell therapy targeting interleukin 13 receptor alpha 2, with MB-108, licensed from Nationwide Children's Hospital.

- In October 2024, Mustang Bio received Orphan Drug Designation from the FDA for MB-108, a herpes simplex virus type 1 oncolytic virus, which is also a component of MB-109, developed to treat malignant glioma.

- In October 2024, U.P. Oncolytics, part of Rosalind Franklin University's Helix 51 biomedical incubator, announced that it received Orphan Drug designation from the FDA's Office of Orphan Products Development for its oncolytic virus-based therapy to treat malignant glioma.

- Leading companies in the Oncolytic Virus market include Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others.

- Emerging acute Oncolytic Virus drugs include Olvi-Vec, RP1, and others.

- Oncolytic virus therapy is rapidly advancing in oncology, driving demand for more targeted and innovative treatments across various solid tumors. By selectively infecting and destroying cancer cells while stimulating anti-tumor immune responses, oncolytic viruses are emerging as a powerful tool in immuno-oncology, especially for cancers resistant to conventional therapies.

To know in detail about the Oncolytic Virus market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Oncolytic Virus Market Forecast [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Oncolytic Virus Overview

Oncolytic viruses represent a novel and promising class of immunotherapies that utilize genetically engineered or naturally occurring viruses to selectively infect, replicate within, and destroy cancer cells while sparing normal tissue. Beyond direct tumor lysis, these viruses also stimulate a systemic anti-tumor immune response by releasing tumor-associated antigens, thereby enhancing the efficacy of other immunotherapies, such as immune checkpoint inhibitors.

Initially studied for melanoma and other skin cancers, the therapeutic potential of OVs has expanded to include a broad range of solid tumors, including glioblastoma, pancreatic, lung, breast, and prostate cancers. The field gained momentum with the FDA approval of Talimogene laherparepvec (T-VEC) for unresectable melanoma, marking a significant step in clinical validation.

Advancements in viral engineering, combination strategies, and delivery methods continue to drive innovation. Several OVs in development are being designed to express immune-modulating agents or function synergistically with existing therapies to overcome resistance and enhance tumor targeting.

Overall, oncolytic virotherapy is redefining the cancer treatment paradigm with its dual-action mechanism-direct oncolysis and immune activation-offering new hope for patients with hard-to-treat and resistant cancers.

Get a free sample of the Oncolytic Virus market report with key insights and emerging therapies here: https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Oncolytic Virus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Oncolytic Virus Epidemiology Segmentation:

The Oncolytic Virus epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

- Total Incident Cases of Selected Cancer Types

- Target Patient Pool of Oncolytic Virus Therapy by Cancer Types

- Treated Cases by Cancer Types

Download the report to understand which factors are driving Oncolytic Virus epidemiology trends @ Oncolytic Virus Epidemiology Forecast [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Oncolytic Virus Drugs Uptake and Pipeline Development Activities

The Oncolytic Virus drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being adopted in the Oncolytic Virus market during the study period. This analysis covers drug uptake, patient adoption of therapies, and the sales performance of each drug.

Additionally, the therapeutics assessment section highlights the drugs with the most rapid uptake, shedding light on the factors driving their widespread use. It also provides a comparative analysis of these drugs based on their market share.

The report further delves into the Oncolytic Virus pipeline development activities, offering key insights into various therapeutic candidates in different stages of development and the major companies behind these innovations. It also covers recent collaborations, acquisitions, mergers, licensing agreements, patent details, and other critical information related to emerging therapies.

Oncolytic Virus Market Outlook

The oncolytic virus market is gaining strong momentum as cancer remains a major global health burden, necessitating the development of more precise and innovative treatments. Oncolytic viruses, with their ability to selectively replicate within tumor cells and trigger robust immune responses, have emerged as a compelling therapeutic strategy in oncology. The market is being propelled by growing R&D activity, increased pharmaceutical investment, and a rapidly expanding clinical trial landscape.

With the success of landmark approvals such as IMLYGIC (Amgen) for melanoma and DELYTACT (Daiichi Sankyo) for glioma, the therapeutic potential of oncolytic viruses is increasingly being recognized. These approvals underscore the evolving role of OVs in modern cancer therapy. As more biotech companies and research institutions advance their pipelines and strategic collaborations continue to grow, oncolytic viruses are poised to become a cornerstone in the future of personalized and immuno-oncology treatment approaches.

Oncolytic Virus Market Strengths

- Oncolytic viruses offer a dual therapeutic benefit-directly lysing tumor cells and activating the host immune system. This unique approach not only targets cancer locally but also supports systemic anti-tumor immunity, making it a promising complement to existing immunotherapies.

- With landmark approvals like IMLYGIC and DELYTACT, and a robust pipeline of candidates under investigation, the field has gained credibility. Ongoing support from regulatory agencies and increased clinical trial activity reflect strong industry confidence and market potential.

Oncolytic Virus Market Weaknesses

- Achieving effective and targeted delivery of oncolytic viruses to tumor sites, especially in non-injectable solid tumors, remains a hurdle. Systemic delivery often encounters immune clearance and limited tumor penetration.

- Large-scale production and quality control of genetically engineered viruses are technically demanding and costly. This can pose significant barriers for smaller biotech firms and delay commercialization timelines.

Scope of the Oncolytic Virus Market Report

- Study Period: 2020-2034

- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

- Key Oncolytic Virus Companies: Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others.

- Key Oncolytic Virus Therapies: Olvi-Vec, RP1, and others.

- Oncolytic Virus Therapeutic Assessment: Oncolytic Virus, currently marketed, and Oncolytic Virus emerging therapies

- Oncolytic Virus Market Dynamics: Oncolytic Virus market drivers and Oncolytic Virus market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- Oncolytic Virus Unmet Needs, KOL's views, Analyst's views, Oncolytic Virus Market Access and Reimbursement

To learn more about the key players and advancements in the Oncolytic Virus treatment landscape, visit the Oncolytic Virus Market Analysis Report [https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Oncolytic Virus Market Report Introduction

2. Executive Summary for Oncolytic Virus

3. SWOT analysis of Oncolytic Virus

4. Oncolytic Virus Patient Share (%) Overview at a Glance

5. Oncolytic Virus Market Overview at a Glance

6. Oncolytic Virus Disease Background and Overview

7. Oncolytic Virus Epidemiology and Patient Population

8. Country-Specific Patient Population of Oncolytic Virus

9. Oncolytic Virus Current Treatment and Medical Practices

10. Oncolytic Virus Unmet Needs

11. Oncolytic Virus Emerging Therapies

12. Oncolytic Virus Market Outlook

13. Country-Wise Oncolytic Virus Market Analysis (2020-2034)

14. Oncolytic Virus Market Access and Reimbursement of Therapies

15. Oncolytic Virus Market Drivers

16. Oncolytic Virus Market Barriers

17. Oncolytic Virus Appendix

18. Oncolytic Virus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=oncolytic-virus-market-set-to-advance-cancer-immunotherapy-frontier-through-2034-says-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.